Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 7/2016

01-07-2016 | Benign Prostatic Hyperplasia (K McVary, Section Editor)

The Effect of LUTS/BPH and Treatments on Ejaculatory Function

Authors: Michelle Herberts, Michael Butcher, Tobias Köhler

Published in: Current Urology Reports | Issue 7/2016

Login to get access

Abstract

As men age, there is an increased incidence of lower urinary tract symptoms (LUTS), often from benign prostatic hyperplasia (BPH) which can adversely affect sexual function. There are many different treatments for these symptoms; however, many of the treatments also affect sexual quality of life, specifically in the realm of ejaculation. Our paper will review the medications, surgical procedures, minimally invasive procedures, and even investigational procedures used to treat LUTS/BPH and the effect they have on ejaculation. The aim of this paper is to help practitioners counsel patients more effectively on treatment options when ejaculation is a concern.
Literature
1.
Woo HH et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9(2):568–75.CrossRefPubMed
2.
Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5(12):2917–24.CrossRefPubMed
3.
4.
Sun J, Zhang X. Pharmacotherapy and herbal treatment of benign prostatic hyperplasia. Front Biosci (Landmark Ed). 2014;19:789–97. United States.CrossRef
5.
Wein AJ et al. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int. 2009;103 Suppl 3:33–41.CrossRefPubMed
6.
Li MK et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. BJU Int. 2008;101(2):197–202.PubMed
7.
Martin DJ, Mulhall JP. Enlarging the scope of managing benign prostatic hyperplasia: addressing sexual function and quality of life. Int J Clin Pract. 2005;59(5):579–90.CrossRefPubMed
8.
Rosen R, Seftel A, Roehrborn CG. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int J Impot Res. 2007;19(5):480–5.CrossRefPubMed
9.
van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287–301. New Zealand.CrossRefPubMed
10.
Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int. 2005;95 Suppl 4:12–8.CrossRefPubMed
11.
Giuliano F, Clement P. Pharmacology for the treatment of premature ejaculation. Pharmacol Rev. 2012;64(3):621–44.CrossRefPubMed
12.
Hellstrom WJ, Giuliano F, Rosen RC. Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment. Urology. 2009;74(1):15–21.CrossRefPubMed
13.
Kim MK et al. An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. Int J Clin Pract. 2010;64:345–50. England.CrossRefPubMed
14.••
Gacci M et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554–66. This is a great article that covers many of the side effects and concerns with the medications dealing with ejaculatory dysfunction in LUTS/BPH. CrossRefPubMed
15.
Rosen RC, Fitzpatrick JM. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int. 2009;104(7):974–83.CrossRefPubMed
16.
Corona G et al. Perceived ejaculate volume reduction in patients with erectile dysfunction: psychobiologic correlates. J Androl. 2011;32(3):333–9.CrossRefPubMed
17.
Gacci M et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809–25.CrossRefPubMed
18.
Nix JW, Carson CC. Medical management of benign prostatic hypertrophy. Can J Urol. 2007;14 Suppl 1:53–7.PubMed
19.
Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int. 2004;94:738–44. England.CrossRefPubMed
20.
Thiyagarajan M. alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. Pharmacology. 2002;65:119–28. 2002 S. Karger AG, Basel: Switzerland.CrossRefPubMed
21.
Yoshimura K et al. A survey of the FAERS database concerning the adverse event profiles of alpha1-adrenoreceptor blockers for lower urinary tract symptoms. Int J Med Sci. 2013;10(7):864–9.CrossRefPubMedPubMedCentral
22.••
Welliver C et al. Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function. Curr Urol Rep. 2014;15(10):441. This is another great paper dealing with all different types of sexual side effects of LUTS/BPH. CrossRefPubMed
23.
Yokoyama T et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol. 2011;18(3):225–30.CrossRefPubMed
24.
25.
Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97 Suppl 2:34–8. discussion 44-5.CrossRefPubMed
26.
Kaplan SA et al. A 5-year retrospective analysis of 5alpha-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66(11):1052–5.CrossRefPubMed
27.
Uckert S, Kuczyk MA, Oelke M. Phosphodiesterase inhibitors in clinical urology. Expert Rev Clin Pharmacol. 2013;6(3):323–32.CrossRefPubMed
28.
Giuliano F et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med. 2013;10(3):857–65.CrossRefPubMed
29.
Suarez O et al. Mirabegron for male lower urinary tract symptoms. Curr Urol Rep. 2013;14(6):580–4.CrossRefPubMed
30.
Chung DE, Sandhu JS. Overactive bladder and outlet obstruction in men. Curr Urol Rep. 2011;12(1):77–85.CrossRefPubMed
31.
Otsuki H et al. Beta3-adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45(1):53–60.CrossRefPubMed
32.•
Calmasini FB et al. The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication? Prostate. 2015;75(4):440–7. As new medications are being used to treat LUTS, it is helpful to know how they may affect sexual function and this article addresses that with mirabegron. CrossRefPubMed
33.
Cirino G et al. Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Proc Natl Acad Sci U S A. 2003;100:5531–6. United States.CrossRefPubMedPubMedCentral
34.
Matsumoto R et al. Expression and functional role of beta3 -adrenoceptors in the human ureter. Int J Urol. 2013;20(10):1007–14.PubMed
35.
Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170(2 Pt 1):649–53.CrossRefPubMed
36.
Liao CH, Kuo YC, Kuo HC. Predictors of successful first-line antimuscarinic monotherapy in men with enlarged prostate and predominant storage symptoms. Urology. 2013;81(5):1030–3.CrossRefPubMed
37.
Hofner K et al. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol. 2010;28(3):353–7.CrossRefPubMed
38.
Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273–5. discussion 2275-6.CrossRefPubMed
39.•
McVary KT et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med. 2014;11(1):279–87. This article looks at how anticholinergics effect sexual function in men while still helping to treat irratative symptoms of LUTS/BPH. CrossRefPubMed
40.
Barry MJ et al. Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol. 2012;30:513–8. United States.CrossRefPubMedPubMedCentral
41.
Zong HT et al. The impact of transurethral procedures for benign prostate hyperplasia on male sexual function: a meta-analysis. J Androl. 2012;33(3):427–34.CrossRefPubMed
42.
Spaliviero M et al. Does Greenlight HPS(™) laser photoselective vaporization prostatectomy affect sexual function? J Endourol. 2010;24(12):2051–7.CrossRefPubMed
43.
Mamoulakis C et al. Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. BJU Int. 2013;112(1):109–20.CrossRefPubMed
44.
Bruyere F. The relationship between photoselective vaporization of the prostate and sexual function. Curr Urol Rep. 2011;12(4):261–4.CrossRefPubMed
45.
Terrasa JB et al. Prospective, multidimensional evaluation of sexual disorders in men after laser photovaporization of the prostate. J Sex Med. 2013;10(5):1363–71.CrossRefPubMed
46.
Elshal AM et al. Male sexual function outcome after three laser prostate surgical techniques: a single center perspective. Urology. 2012;80(5):1098–104.CrossRefPubMed
47.
Meng F et al. Change of sexual function in patients before and after Ho:YAG laser enucleation of the prostate. J Androl. 2007;28(2):259–61.CrossRefPubMed
48.
Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res. 2007;19(6):544–50.CrossRefPubMed
49.
Frieben RW et al. The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review. Asian J Androl. 2010;12:500–8. China.CrossRefPubMedPubMedCentral
50.
Elhilali MM et al. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol. 2013;189(4):1421–6.CrossRefPubMedPubMedCentral
51.•
Dixon CM et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum® system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015;7:13–8. This article gave a nice review of some newer therapies with steam that seems to be promising at this point. PubMedPubMedCentral
Metadata
Title
The Effect of LUTS/BPH and Treatments on Ejaculatory Function
Authors
Michelle Herberts
Michael Butcher
Tobias Köhler
Publication date
01-07-2016
Publisher
Springer US
Published in
Current Urology Reports / Issue 7/2016
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-016-0604-4

Other articles of this Issue 7/2016

Current Urology Reports 7/2016 Go to the issue

Urothelial Cancer (A Sagalowsky, Section Editor)

Gastrointestinal Complications in Patients Who Undergo Radical Cystectomy with Enhanced Recovery Protocol

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Correlating Preoperative Imaging with Histologic Subtypes of Renal Cell Carcinoma and Common Mimickers

Benign Prostatic Hyperlasia (K McVary, Section Editor)

Phytotherapy for Benign Prostatic Hyperplasia

Regenerative Medicine (A Atala, Section Editor)

In Vitro Spermatogenesis: How Far from Clinical Application?

New Imaging Techniques (A Rastinehad and S Rais-Bahrami, Section Editors)

Prostate Artery Embolization as a New Treatment for Benign Prostate Hyperplasia: Contemporary Status in 2016